Alkermes plc (ALKS)
ROA
Obliczenia
|
2023/Q4 (31 gru 2023) |
2023/Q3 (30 wrz 2023) |
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | 355 757 | 214 724 | 102 992 | -164 209 | -158 267 | -129 140 | -94 154 | -61 654 |
| Aktywa razem | w tys. USD | 2 136 220 | 2 279 230 | 2 187 180 | 1 922 730 | 1 963 980 | 1 941 900 | 1 957 420 | 1 977 840 |
| ROA | 16,65% | 9,42% | 4,71% | -8,54% | -8,06% | -6,65% | -4,81% | -3,12% |
2023/Q4 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $355 757K ÷ $2 136 220K
= 16,65%
Analiza porównawcza
2023/Q4
Nazwa spółki
Symbol
ROA
Alkermes plc
ALKS
16,65%
Arrowhead Pharmaceuticals Inc.
ARWR
-47,39%
Corcept Therapeutics Inc
CORT
17,08%
Cytokinetics Inc
CYTK
-63,84%
Harmony Biosciences Holdings Inc
HRMY
15,88%
Organon & Co.
OGN
8,48%
Pacira BioSciences Inc
PCRX
2,66%
Perrigo Company plc
PRGO
-0,12%
Prestige Consumer Healthcare Inc
PBH
-2,42%
Schrodinger Inc
SDGR
5,07%
Supernus Pharmaceuticals Inc
SUPN
0,10%